PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Hoelscher, M. ; Barros-Aguirre, D.* ; Dara, M.* ; Heinrich, N.* ; Sun, E.* ; Lange, C.* ; Tiberi, S.* ; Wells, C.M.*

Candidate anti-tuberculosis medicines and regimens under clinical evaluation.

Clin. Microbiol. Infect. 30, 1131-1138 (2024)
Verlagsversion Postprint DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND: Tuberculosis (TB) is the leading cause of mortality by an infectious disease world-wide. Despite national and international efforts, the world is not on track to end TB by 2030. Antibiotic treatment of TB is longer than for most infectious diseases and complicated by frequent adverse events. To counter emerging Mycobacterium tuberculosis drug resistance and provide effective, safe drug treatments of shorter duration, novel anti-TB medicines and treatment regimens are needed. Through a joint global effort, more candidate medicines are in the clinical phases of drug development than ever before. OBJECTIVES: To review anti-TB medicines and treatment regimens under clinical evaluation for the future treatment of drug-susceptible and drug-resistant TB. SOURCES: Pre-clinical and clinical studies on novel anti-TB drugs. CONTENT: Description of novel protein synthesis inhibitors (oxazolidinones and oxaboroles), respiratory chain inhibitors (diarylquinolines and cytochrome bc1 complex inhibitor), cell wall inhibitors (DprE1 inhibitors, thioamides and carbapenems) and cholesterol metabolism inhibitor currently evaluated in clinical trials and novel clinical trial platforms for the evaluation of treatment regimens, rather than single entities. IMPLICATIONS: A large number of potential anti-TB candidate medicines and innovations in clinical trial design for the evaluation of regimens, rather than single medicines, provide hope for improvements in the treatment of TB.
Impact Factor
Scopus SNIP
Altmetric
10.900
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Clinical Trials ; Drug Classes ; Platform Trials ; Tb ; Unite4tb; Mycobacterium-tuberculosis; Resistant Tuberculosis; Drug; Bedaquiline; Pretomanid; Delamanid; Moxifloxacin; Q203
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 1198-743X
e-ISSN 1469-0691
Zeitschrift Clinical Microbiology and Infection
Quellenangaben Band: 30, Heft: 9, Seiten: 1131-1138 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort 125 London Wall, London, England
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Global Health (UGH)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-540001-003
Förderungen German Ministry for Edu-cation and Research (BMBF)
EDCTP2 programme
German Center for Infection Research (DZIF)
German Center of Infection Research
Bill & Melinda Medical Research Institute
Otsuka Novel Products GmbH
DOI 10.1016/j.cmi.2024.06.016
WOS ID 001295524500001
Scopus ID 85198218279
PubMed ID 38909687
Erfassungsdatum 2024-06-26
[➜Korrektur melden]